Cytokinetics falls on Phase III ALS readout for tirasemtiv

Cytokinetics Inc. (NASDAQ:CYTK) fell $2.85 (26%) to $8.25 on Tuesday after the company said it will suspend development of tirasemtiv as the candidate missed the primary and secondary endpoints in the Phase III VITALITY-ALS trial to treat

Read the full 370 word article

User Sign In